Thomas S. Mchugh - Dec 7, 2021 Form 4 Insider Report for AVADEL PHARMACEUTICALS PLC (AVDL)

Role
Chief Financial Officer
Signature
/s/ Jerad Seurer, as Attorney-in-Fact
Stock symbol
AVDL
Transactions as of
Dec 7, 2021
Transactions value $
$0
Form type
4
Date filed
12/9/2021, 05:44 PM
Next filing
May 31, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVDL Stock Option (Right to Buy) Award $0 +150K $0.00 150K Dec 7, 2021 ADSs 150K $8.20 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Options become exercisable as to 37,500 ADSs on each of the first four anniversaries after the 12/07/2021 grant date.
F2 The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.